| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5825972 | Current Opinion in Pharmacology | 2015 | 7 Pages |
Abstract
The development of MEK inhibitors has led to improved progression-free survival in patients with mutant BRAFV600 cancers when used in combination with BRAF inhibitors. However, resistance to combination therapy remains an issue. This review summarizes our current understanding of the role of MEK in cancer cell proliferation and the mechanisms which lead to resistance in patients. Specific adverse events, which have been linked to the MEK inhibitor class, have been described. Future combinations of MEK inhibitors with other cancer therapy options, currently under investigation in clinical trials, are also discussed.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Ian E Templeton, Luna Musib,